ArticleTargeted oncology2025

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Fenneke Zwierenga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.